NCT04858256View on ClinicalTrials.gov

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions
T-Cell NeoplasmLymphoproliferative Disorders
Interventions
DRUG

Pacritinib

Pacritinib will be dosed at 200mg twice daily.

Trial Locations (6)

15232

NOT_YET_RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

27710

RECRUITING

Duke Cancer Institute, Durham

33612

NOT_YET_RECRUITING

Moffitt Cancer Center, Tampa

43202

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

48109

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

91010

RECRUITING

City of Hope, Duarte

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER